Background:

Pulmonary hypertension (PH) is high blood pressure in the blood vessels of the lungs. It can lead to heart failure and death if not treated. Researchers want to create a repository of blood samples and health information collected from people with PH. They hope to use this information to find better ways to diagnose and treat PH.

Objective:

To collect blood samples and health information from people suspected of or diagnosed with PH.

Eligibility:

People aged 18 years and older who have or may have PH.

Design:

Researchers will collect information from participants medical records.

Participants will have blood drawn from a vein. About 3 tablespoons will be collected during the study visit. The visit will last about 1 hour.

Participants may choose to provide new blood samples at follow-up visits. Updated medical information may also be collected.

Participants may continue to participate as long as the study is ongoing. Participants may opt out of providing new blood samples but remain in the study.

All study samples will be stored at the National Institutes of Health. Health information will be stored in secure databases.

Study Description:

This study aims to establish a biorepository based on the World Symposium Pulmonary Hypertension (PH) Groups 1-5. In the future, IRB approved protocols may use these blood samples to discover novel, biologically relevant, non-invasive PH biomarkers. In combination with clinical data these potential biomarkers will be used to distinguish PH groups, elucidate underlying molecular phenotypes, predict clinically relevant outcomes, as well as discriminate healthy (healthy subjects will not be enrolled under this protocol) from PH disease states, and differentiate patients with PH from patients without PH. To this end, multimodal genomic, metabolomic, and proteomic assays will eventually be developed and used.

Objectives:

Primary:

Develop a multi-center biorepository of patients suspected of or diagnosed with PH Group 1-5.

Secondary:

Collect the specific data attributes that may be used in the future to determine whether multimodal genomic, metabolomic or proteomic biomarkers, in combination with clinical data, can:

-Elucidate molecular phenotypes that distinguish between patients across PH groups

Predict clinically relevant outcomes (i.e., disease severity, disease progression, response to therapy, transplant free survival).

• INCLUSION CRITERIA:
• Provision of signed and dated informed consent form
• Males and females aged >=18 years old
• Suspected of or diagnosed with PH
• Able to understand and willing to sign a written informed consent document

EXCLUSION CRITERIA:

Any individual who does not meet all inclusion criteria or is deemed by the local investigator not to be a blood draw candidate will be excluded from participating in this study.

The study population will consist of adult male and female participants older than 18 years who are suspected of having or have been diagnosed with pulmonary hypertension (PH). Eligible individuals must be able to understand the study requirements and be willing to provide written informed consent by signing and dating the informed consent form prior to participation.

All IPD that underlie results in a publication.

Within 12 months from publication

Published IPD will be shared upon request to the research team.